Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye in conjunction with a directed new issue of shares
Mandate

Vinge advises Smart Eye in conjunction with a directed new issue of shares

October 06, 2020 Capital Markets and Public M&A

Vinge has advised Smart Eye AB in connection with a directed new issue of 1 511 898 new shares at a subscription price of SEK 125 per share, which means that Smart Eye will acquire MSEK 189 prior to issue costs.

The subscription price has been determined through an accelerated book building procedure and corresponds to a discount of 2.9 per cent compared with the volume‑weighted average price on Nasdaq First North Growth Market on 5 October 2020.

Vinge’s team consisted of Anders Strid, Edin Agic and Jacob Benzow.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025